Weight-loss weariness and Trump threats wipe $250bn off Novo Nordisk and Eli Lilly Financial TimesThe battle of the obesity drug heavyweights Fierce PharmaNavigating the Storm: Assessing Novo Nordisk’s GLP-1 Market Exposure Amid Legal and Financial Turbulence AInvestNovo Nordisk (NVO) vs Eli Lilly (LLY): Who’s Winning the Weight-Loss Drug War? Money MorningEli Lilly Vs. Novo Nordisk: Correction Overly Done – GLP-1 Market Leadership/ Robust Pipelines Ahead Seeking Alpha